Literature DB >> 7689450

The use of quinolones in developing countries.

E Rodríguez-Noriega1, R Morfin-Otero, S Esparza-Ahumada.   

Abstract

The size of the antibiotic market in developing countries is double that seen in developed countries. There are some valid reasons for this difference, one of which is the higher frequency of diverse infections in the developing world. However, other factors are involved: for example, antibiotics are available without prescription, package insert information is poor, and there is no national antibiotic usage programme, all of which encourage inappropriate antibacterial use. When an antibiotic becomes widely prescribed by physicians, this is interpreted by the general public as meaning that the antibiotic is useful for all types of infections and the process of automedication begins. The newer quinolones, other new antibiotics, and indeed all antimicrobials should be available only by prescription. A package insert that includes all pertinent information should be provided, and each country should implement a comprehensive national antibiotic usage programme. Only through these measures will bacterial resistance be controlled and the effectiveness of each antibiotic class be maintained.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7689450     DOI: 10.2165/00003495-199300453-00009

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  12 in total

Review 1.  New aspects of antimicrobial resistance and the resulting therapeutic dilemmas.

Authors:  B E Murray
Journal:  J Infect Dis       Date:  1991-06       Impact factor: 5.226

2.  Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs medical center.

Authors:  R R Muder; C Brennen; A M Goetz; M M Wagener; J D Rihs
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

3.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

Review 4.  Resistance of bacteria to antibacterial agents: report of Task Force 2.

Authors:  T F O'Brien
Journal:  Rev Infect Dis       Date:  1987 May-Jun

Review 5.  Health and economic impacts of antimicrobial resistance.

Authors:  S D Holmberg; S L Solomon; P A Blake
Journal:  Rev Infect Dis       Date:  1987 Nov-Dec

6.  Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.

Authors:  A L Barry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

Review 7.  Antimicrobial resistance in hospital organisms and its relation to antibiotic use.

Authors:  J E McGowan
Journal:  Rev Infect Dis       Date:  1983 Nov-Dec

8.  Increasing resistance of Staphylococcus aureus to ciprofloxacin.

Authors:  T E Daum; D R Schaberg; M S Terpenning; W S Sottile; C A Kauffman
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

9.  Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes.

Authors:  C C Sanders; W E Sanders; R V Goering; V Werner
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

10.  Development of resistance in Pseudomonas aeruginosa to imipenem, norfloxacin, and ciprofloxacin during therapy: proof provided by typing with a DNA probe.

Authors:  J W Ogle; L B Reller; M L Vasil
Journal:  J Infect Dis       Date:  1988-04       Impact factor: 5.226

View more
  1 in total

Review 1.  Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy.

Authors:  R Davis; H M Bryson
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.